| 000 | 02742nam a22003615i 4500 | ||
|---|---|---|---|
| 001 | 394226 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102123111.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 221019s2022 si | s |||| 0|eng d | ||
| 020 | _a9789811955952 | ||
| 024 | 7 |
_a10.1007/978-981-19-5595-2 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC |
||
| 100 | 1 |
_aGanguly, Dipyaman _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut |
|
| 245 | 1 | 0 |
_aPlasmacytoid Dendritic Cells _cby Dipyaman Ganguly |
| 250 | _a1st edition 2022 | ||
| 264 | 1 |
_aSingapore _bSpringer International Publishing _c2022 |
|
| 300 |
_a1 recurso en línea (IX, 163 páginas) _b1 illus |
||
| 336 |
_atexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_aarchivo de texto _bPDF |
||
| 505 | 0 | _aChapter 1_Dendritic cells and the basic principles of immune functions -- Chapter 2_Discovery of a new dendritic cell -- Chapter 3_Hematopoietic origins of plasmacytoid dendritic cells -- Chapter 4_Molecular regulation of plasmacytoid dendritic cell identity -- Chapter 5_Type I interferon production by plasmacytoid dendritic cells -- Chapter 6_Tolerogenic functions of plasmacytoid dendritic cells -- Chapter 7_Plasmacytoid dendritic cells and infections -- Chapter 8_Plasmacytoid dendritic cells in autoimmunity and allergy -- Chapter 9_Plasmacytoid dendritic cells and metabolic disorders -- Chapter 10_ Plasmacytoid dendritic cells and cancer -- Chapter 11_Therapeutic targeting of plasmacytoid dendritic cells -- Chapter 12_Experimental methodology for plasmacytoid dendritic cells. | |
| 520 | _aThis book provides a systematic review of the development, function, and patho-physiologic role of plasmacytoid dendritic cells (pDCs) in humans. The chapters of the book discuss the origin and discovery, hematopoietic development as well as molecular regulation of pDCs in the context of immune activation as well as immune tolerance. It also discusses the role of pDCs in human diseases, including infections, autoimmune/inflammatory diseases, cancers and metabolic disorders, and opportunities for pDC‐targeting therapies in these varied clinical contexts. . | ||
| 776 | 0 | 8 |
_iPrinted edition: _z9789811955945 |
| 776 | 0 | 8 |
_iPrinted edition: _z9789811955969 |
| 776 | 0 | 8 |
_iPrinted edition: _z9789811955976 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-19-5595-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 988 | _aSpringer_BiomedLife_2022 | ||
| 999 |
_c394226 _d394226 |
||